5 things to know about Hookipa Pharma ahead of its IPO

Hookipa Pharma Inc., a biotech that’s using arenavirus-based platforms to develop treatments targeting infectious diseases and cancers, set terms for its initial public offering shares this week, saying it will offer 6.7 million shares priced at $14 to $16 each.

At the midpoint of that range, the deal will raise about $100.5 million.

Hookipa HOOK, +0.00% has applied to trade on the Nasdaq exchange under the ticker symbol “HOOK.”

Only one of Hookipa’s six pipeline drugs is in the clinical stage of development. It’s a therapy called HB-101, meant to treat cytomegalovirus (CMV), a common virus that is generally clinically benign in healthy people but can cause serious issues in people who are immunocompromised.

>>> Original Source <<<